Patents Assigned to Apogenix GmbH
  • Composition comprising a mixture of CD95-Fc isoforms and methods of producing same
    Patent number: 9315570
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Grant
    Filed: July 18, 2013
    Date of Patent: April 19, 2016
    Assignee: APOGENIX GMBH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Trail collectin fusion proteins
    Patent number: 9212211
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: December 15, 2015
    Assignee: APOGENIX GMBH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • COMPOSITION COMPRISING A MIXTURE OF CD95-FC ISOFORMS
    Publication number: 20150225475
    Abstract: The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition.
    Type: Application
    Filed: July 18, 2013
    Publication date: August 13, 2015
    Applicant: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • INHIBITORS OF THE CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS
    Publication number: 20150166632
    Abstract: The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a method for the diagnosis of MDS.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 18, 2015
    Applicant: APOGENIX GmbH
    Inventors: Harald Fricke, Michaela Fontenay
  • SHORTENED CD95-FC VARIANTS
    Publication number: 20150166633
    Abstract: The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.
    Type: Application
    Filed: July 18, 2013
    Publication date: June 18, 2015
    Applicant: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Single chain fusion polypeptides comprising soluble light cytokine domains
    Patent number: 8921519
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: May 24, 2013
    Date of Patent: December 30, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • TNF superfamily collectin fusion proteins and encoding nucleic acids
    Patent number: 8907063
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: February 25, 2013
    Date of Patent: December 9, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • FUSION PROTEINS FORMING TRIMERS
    Publication number: 20140171622
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Application
    Filed: January 21, 2014
    Publication date: June 19, 2014
    Applicant: APOGENIX GMBH
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • Fusion proteins forming trimers
    Patent number: 8664366
    Abstract: The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide. Further the invention refers to a nucleic acid encoding the said fusion protein. The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: March 4, 2014
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Marcus Branschaedel, Christian Gieffers, Meinolf Thiemann
  • TNFSF SINGLE CHAIN MOLECULES
    Publication number: 20140056843
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: May 24, 2013
    Publication date: February 27, 2014
    Applicant: APOGENIX GMBH
    Inventors: Oliver HILL, Christian GIEFFERS, Meinolf THIEMANN
  • Multimeric TNF receptor fusion proteins and nucleic acids encoding same
    Patent number: 8592557
    Abstract: The present invention refers to fusion proteins comprising a TNF receptor family extracellular domain fused to a trimerization domain, and a nucleic acid molecule encoding the fusion protein. The fusion protein may be present as a trimeric complex. It is suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: June 15, 2009
    Date of Patent: November 26, 2013
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Carmen Fischer
  • TNF superfamily member light fusion proteins
    Patent number: 8580273
    Abstract: The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: February 23, 2012
    Date of Patent: November 12, 2013
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • TNF SUPERFAMILY COLLECTIN FUSION PROTEINS
    Publication number: 20130178604
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: February 25, 2013
    Publication date: July 11, 2013
    Applicant: APOGENIX GMBH
    Inventor: APOGENIX GMBH
  • Single-chain TNFSF fusion polypeptides
    Patent number: 8450460
    Abstract: The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins. The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 18, 2009
    Date of Patent: May 28, 2013
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • Collectin fusion proteins comprising TNF or trail
    Patent number: 8383774
    Abstract: The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule. The fusion protein is present as a trimeric complex or as an oligomer thereof. The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: February 26, 2013
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann, Marcus Branschädel
  • CD95L or trail fusion proteins
    Patent number: 8147843
    Abstract: The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.
    Type: Grant
    Filed: August 28, 2007
    Date of Patent: April 3, 2012
    Assignee: Apogenix GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • CD95-Fc fusion proteins
    Patent number: 8007813
    Abstract: The invention relates to fusion proteins comprising at least a first domain and a second domain selected from a constant Fc immunoglobulin domain.
    Type: Grant
    Filed: March 26, 2004
    Date of Patent: August 30, 2011
    Assignees: Apogenix GmbH, Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts
    Inventor: Henning Walczak
  • METHODS AND COMPOSITIONS FOR PREVENTING RADIATION-INDUCED PNEUMONITIS
    Publication number: 20110171212
    Abstract: Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods. A preferred composition comprises a CD95/CD95L inhibitor. Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm.
    Type: Application
    Filed: November 10, 2010
    Publication date: July 14, 2011
    Applicant: APOGENIX GmbH
    Inventors: Claus Belka, Jörg Herbst
  • TNF SUPERFAMILY FUSION PROTEINS
    Publication number: 20110027218
    Abstract: The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein. The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.
    Type: Application
    Filed: August 28, 2007
    Publication date: February 3, 2011
    Applicant: APOGENIX GmbH
    Inventors: Oliver Hill, Christian Gieffers, Meinolf Thiemann
  • ANTIBODY SPECIFIC FOR HUMAN IL-4 FOR THE TREATMENT OF CANCER
    Publication number: 20100297110
    Abstract: The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.
    Type: Application
    Filed: March 21, 2007
    Publication date: November 25, 2010
    Applicant: APOGENIX GMBH
    Inventors: Thomas Hoeger, Juergen Gamer, Giorgio Stassi, Matilde Todaro